Chirfi Guindo Sells 15,000 Shares of Merck & Co., Inc. (NYSE:MRK) Stock

Key Points

• Merck EVP Chirfi Guindo sold 15,000 shares at an average price of $131, generating $1.965 million and reducing his ownership by 24.35% to 46,613 shares.
• Merck reported quarterly revenue of $16.61 billion, exceeding estimates, while adjusted EPS of $(0.13) beat expectations by $0.13; revenue increased 5.1% year over year.
• The company declared a quarterly dividend of $0.85 per share, equivalent to $3.40 annually and a 2.6% yield. Analysts maintain a “Moderate Buy” consensus with an average price target of $134.56.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) EVP Chirfi Guindo sold 15,000 shares of the firm's stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the completion of the transaction, the executive vice president owned 46,613 shares in the company, valued at $6,106,303. The trade was a 24.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Merck & Co., Inc. Stock Performance

Merck & Co., Inc. stock traded up $0.24 on Friday, reaching $128.61. 6,425,060 shares of the stock were exchanged, compared to its average volume of 10,766,726. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a twelve month low of $77.58 and a twelve month high of $135.05. The firm has a fifty day moving average price of $123.78 and a two-hundred day moving average price of $119.04. The stock has a market cap of $317.64 billion, a PE ratio of 102.89, a PEG ratio of 5.14 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.The company had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. During the same period last year, the business posted $2.13 earnings per share. The firm's revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Sell-side analysts anticipate that Merck & Co., Inc. will post 2.72 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.6%. Merck & Co., Inc.'s payout ratio is 272.00%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Norges Bank acquired a new stake in Merck & Co., Inc. during the fourth quarter valued at approximately $3,997,933,000. Wellington Management Group LLP boosted its stake in Merck & Co., Inc. by 14.8% in the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company's stock valued at $9,098,196,000 after buying an additional 11,156,354 shares in the last quarter. Cardano Risk Management B.V. bought a new stake in Merck & Co., Inc. in the fourth quarter valued at $1,012,530,000. Jennison Associates LLC bought a new stake in Merck & Co., Inc. in the fourth quarter valued at $585,192,000. Finally, Price T Rowe Associates Inc. MD raised its stake in Merck & Co., Inc. by 37.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 18,753,390 shares of the company's stock worth $1,973,983,000 after acquiring an additional 5,152,069 shares in the last quarter. Institutional investors own 76.07% of the company's stock.

Analysts Set New Price Targets

MRK has been the subject of several research analyst reports. Royal Bank Of Canada reiterated an "outperform" rating and set a $142.00 target price on shares of Merck & Co., Inc. in a research note on Wednesday, July 8th. UBS Group increased their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a "buy" rating in a research note on Monday, April 13th. Citigroup initiated coverage on Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a "neutral" rating and a $125.00 price target on the stock. Barclays raised their price objective on Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 29th. Finally, Bank of America upped their target price on Merck & Co., Inc. from $130.00 to $141.00 and gave the company a "buy" rating in a research note on Tuesday, June 30th. Thirteen equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, Merck & Co., Inc. currently has a consensus rating of "Moderate Buy" and a consensus price target of $134.56.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source